Cet article est réservé aux membres

Déjà membre ?

Log In

Not a member ?

Free registration
BAYER AG : Jefferies gives a Neutral rating ZD
Bayer: results for prostate cancer treatment CF
BAYER AG : JP Morgan reiterates its Neutral rating ZD
Bayer's Prostrate Cancer Therapy Cuts Risk of Radiological Progression, Death in Late-stage Trial MT
RTW Biotech half-year net asset value rises amid "challenging markets" AN
German Shares Advance as ECB Delivers Widely Expected Rate Cut MT
Bayer wins another glyphosate lawsuit in the USA DP
Bayer's Monsanto Secures Favorable Verdict in Roundup Weedkiller Philadelphia Trial MT
Jury rules in favor of Bayer's Monsanto in Philadelphia trial over Roundup RE
Bayer to present results from AMD trials CF
Agrochemicals group Syngenta cuts jobs in Basel RE
Bayer falls in recovered market environment - glyphosate remains in focus DP
Bayer wants to take glyphosate lawsuits to the highest US court RE
Goldman rates Bayer at 'Neutral' - Target 30 euros DP
BAYER AG : Goldman Sachs remains Neutral ZD
Study: Agriculture could significantly reduce greenhouse gases DP
Bayer's Finerenone Cuts Risk of New-onset Diabetes in Late-stage Trial MT
Bayer's OcuClick Secures Approval from European Medicines Agency MT
BAYER AG : UBS sticks Neutral ZD
Bayer: receives EMA approval CF
Bayer: last-minute presentations at ESMO congress CF
Veeva Systems: leader in cloud solutions for the life sciences industry Our Logo
Bayer's bottoming out continues to take shape - BofA commentary DP
Bayer gains significantly - focus on US glyphosate dispute DP
Bayer: new data for menopause treatment CF
Chart Bayer AG
More charts
Logo Bayer AG
Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (48.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.7%); - other (0.5%). Net sales are distributed geographically as follows: Germany (5.1%), Switzerland (1.2%), Europe-Middle East-Africa (23.2%), the United States (30.6%), North America (3.5%), China (7.6%), Asia-Pacific (10%), Brazil (10.4%) and Latin America (8.4%).
Employees
96,567
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
27.46EUR
Average target price
35.59EUR
Spread / Average Target
+29.59%
Consensus
  1. Stock Market
  2. Equities
  3. BAYN Stock
  4. News Bayer AG
  5. Bayer's Heart Drug Lowers Cardiovascular Death, Hospitalizations in Late-stage Study
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities. Last hours!
BENEFIT NOW